CN112996910A - 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法 - Google Patents

与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法 Download PDF

Info

Publication number
CN112996910A
CN112996910A CN201980059583.6A CN201980059583A CN112996910A CN 112996910 A CN112996910 A CN 112996910A CN 201980059583 A CN201980059583 A CN 201980059583A CN 112996910 A CN112996910 A CN 112996910A
Authority
CN
China
Prior art keywords
domain
polypeptide
monomer
domain monomer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980059583.6A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·兰辛
D·奥尔蒂斯
A·曼宁
L·鲁蒂茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CN112996910A publication Critical patent/CN112996910A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980059583.6A 2018-07-11 2019-07-11 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法 Pending CN112996910A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696711P 2018-07-11 2018-07-11
US62/696711 2018-07-11
PCT/US2019/041306 WO2020014419A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1

Publications (1)

Publication Number Publication Date
CN112996910A true CN112996910A (zh) 2021-06-18

Family

ID=69141681

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980059583.6A Pending CN112996910A (zh) 2018-07-11 2019-07-11 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法

Country Status (11)

Country Link
US (1) US20210147549A1 (https=)
EP (1) EP3820998A4 (https=)
JP (1) JP2021530989A (https=)
KR (1) KR20210044782A (https=)
CN (1) CN112996910A (https=)
AU (1) AU2019299935A1 (https=)
BR (1) BR112021000383A2 (https=)
CA (1) CA3106108A1 (https=)
IL (1) IL280038A (https=)
MX (1) MX2021000281A (https=)
WO (1) WO2020014419A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024219897A1 (ko) * 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
WO2024219894A1 (ko) * 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
CN106661125A (zh) * 2014-05-02 2017-05-10 动量制药公司 涉及工程化Fc构建体的组合物和方法
CN106939047A (zh) * 2016-01-04 2017-07-11 钜川生物医药 一种pd-l1抗体及其制备方法
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO2017161976A1 (en) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
CN107405399A (zh) * 2015-01-02 2017-11-28 戴埃克斯有限公司 针对血浆激肽释放酶和因子xii的双特异性抗体
WO2018009466A1 (en) * 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018115262A1 (en) * 2016-12-23 2018-06-28 Innate Pharma Heterodimeric antigen binding proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201595T1 (hr) * 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
AU2013229488B2 (en) * 2012-03-08 2017-12-07 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
PH12017501857B1 (en) * 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
CA3000386A1 (en) * 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
BR112018074056A2 (pt) * 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
CN106661125A (zh) * 2014-05-02 2017-05-10 动量制药公司 涉及工程化Fc构建体的组合物和方法
CN107405399A (zh) * 2015-01-02 2017-11-28 戴埃克斯有限公司 针对血浆激肽释放酶和因子xii的双特异性抗体
CN106939047A (zh) * 2016-01-04 2017-07-11 钜川生物医药 一种pd-l1抗体及其制备方法
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO2017161976A1 (en) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
CN108779180A (zh) * 2016-03-23 2018-11-09 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体
WO2018009466A1 (en) * 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018115262A1 (en) * 2016-12-23 2018-06-28 Innate Pharma Heterodimeric antigen binding proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEE, J.等: "immunoglobulin lambda chain variable region, partial [Homo sapiens]", 《GENBANK》 *
LIU, K.等: "Chain H, Avelumab H Chain", 《GENBANK》 *
ZHANG F等: "Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab", 《ONCOTARGET》, vol. 8, no. 52, pages 90215 - 90224, XP055895504, DOI: 10.18632/oncotarget.21652 *
佘由: "抗PD-L1单抗及EGFR-TKI对EGFR敏感突变肺癌细胞PD-L1的表达及T细胞的影响", 《中国硕士学位论文全文数据库医药卫生科技辑》, no. 2017, pages 072 - 130 *

Also Published As

Publication number Publication date
WO2020014419A8 (en) 2021-12-02
CA3106108A1 (en) 2020-01-16
JP2021530989A (ja) 2021-11-18
AU2019299935A1 (en) 2021-02-18
KR20210044782A (ko) 2021-04-23
EP3820998A4 (en) 2022-04-27
EP3820998A2 (en) 2021-05-19
MX2021000281A (es) 2021-11-12
BR112021000383A2 (pt) 2021-04-06
WO2020014419A3 (en) 2020-02-20
WO2020014419A2 (en) 2020-01-16
US20210147549A1 (en) 2021-05-20
IL280038A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
CN113395978A (zh) 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
JP2020514301A (ja) 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CN113194990A (zh) 与靶向CD38的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN112996910A (zh) 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN113164590A (zh) 与靶向CCR4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN113382749A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN113164592A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
BR112021000393A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado
JP2022548925A (ja) ＣＤ３８を標的とした改変されたＦｃ抗原結合ドメイン構築物に関する組成物及び方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210618